About verona pharma - VRNA
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
VRNA At a Glance
Verona Pharma Plc
3 More London Riverside
London, Greater London SE1 2RE
| Phone | 44-203-283-4200 | Revenue | 42.30M | |
| Industry | Pharmaceuticals: Major | Net Income | -173,490,972.34 | |
| Sector | Health Technology | Employees | 209 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VRNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 89.526 |
| Price to Book Ratio | 19.212 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -22.844 |
| Enterprise Value to Sales | 82.976 |
| Total Debt to Enterprise Value | 0.035 |
VRNA Efficiency
| Revenue/Employee | 202,376.988 |
| Income Per Employee | -830,100.346 |
| Receivables Turnover | 1.135 |
| Total Asset Turnover | 0.108 |
VRNA Liquidity
| Current Ratio | 10.627 |
| Quick Ratio | 10.481 |
| Cash Ratio | 9.366 |
VRNA Profitability
| Gross Margin | 91.391 |
| Operating Margin | -365.73 |
| Pretax Margin | -394.354 |
| Net Margin | -410.175 |
| Return on Assets | -44.35 |
| Return on Equity | -76.454 |
| Return on Total Capital | -53.013 |
| Return on Invested Capital | -55.466 |
VRNA Capital Structure
| Total Debt to Total Equity | 59.984 |
| Total Debt to Total Capital | 37.494 |
| Total Debt to Total Assets | 25.873 |
| Long-Term Debt to Equity | 59.436 |
| Long-Term Debt to Total Capital | 37.151 |